US3125491A - Chew able hematinic vitamin tablet - Google Patents

Chew able hematinic vitamin tablet Download PDF

Info

Publication number
US3125491A
US3125491A US3125491DA US3125491A US 3125491 A US3125491 A US 3125491A US 3125491D A US3125491D A US 3125491DA US 3125491 A US3125491 A US 3125491A
Authority
US
United States
Prior art keywords
tablet
ascorbic acid
iron
core
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Application granted granted Critical
Publication of US3125491A publication Critical patent/US3125491A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • This invention relates to novel medicinal chewable tablets. More particularly, this invention relates to a tablet superimposed on a second tablet to form a twolayered tablet, one of these layers consisting of a sugar compression-coated core containing a form of vitamin C, the other layer consisting of a granulation of therapeutic ferrous iron.
  • the chewable tablet of this invention is especially useful for combining incompatible medicaments such as ascorbic acid and iron, in a pleasant tasting single dosage unit.
  • compositions containing iron for oral and parenteral use are usually administered in concentrated form to people sufiiering from iron deficiency anemia.
  • ferrous iron as the sulfate, fumarate, saccharide, gluconate, lactate, etc., and a form of vitamin C such as ascorbic acid, for use in treating iron deficiency anemias, is well-known.
  • ferrous fumarate is well tolerated and generally preferred.
  • chewable hematinic tablets are preferred when people are reluctant to take tablets or capsules because of swallowing difiiculties. Children are particularly a problem in this regard. It would also be an advantage to make available to people who take hematinics rather regularly, a pleasant tasting chewable dosage form containing both ascorbic acid and iron in therapeutic amounts.
  • an oral dosage form such as a chewable tablet containing these therapeutic agents, however, prevents certain difficulties, because of the oxidizing effects of iron on ascorbic acid, and the lability of ascorbic acid to oxygen and moisture, especially at higher temperatures. Furthermore, when ascorbic acid decomposes, a gas evolves which could be hazardous in an air-tight package.
  • hematinic tablets have been prepared with granulations of ascorbic acid and iron compressed into a single tablet separated by an inert middle layer.
  • the iron layer of one tablet is in contact with the ascorbic layer of another tablet, consequently oxidation of the ascorbic acid may occur during storage.
  • This oxidation can be prevented by coating these tablets with sugars, fats, waxes, polyethylene glycol or other known coatings.
  • this extra step would add to the manufacturing cost, and in the case of the sugar coating, would add to the unwanted bulk of the tablet.
  • a stable, pleasant tasting, two-layered chewable hematinic tablet is prepared as follows:
  • the sugar coating on the ascorbic acid must be com- 3,125,491 lc Patented Mar. 17, 1964 pression-coated as is described in Remmington, Practice of Pharmacy, 11th edition, page 406 (1956). Essentially this step involves actually compressing a coating on a core, usually with a tablet press. If the core is pancoated, for instance, the sugar coating is subject to cracking when the iron granulation is compressed superimposed thereon. The sugar must be compression-coated onto the ascorbic acid core in order to produce the two layered tablet of this invention.
  • Compression should be carried out preferably under low humidity conditions and with thoroughly dried granulations because of the adverse effect of moisture on the ascorbic acid.
  • the arrangement of the active ingredients in the twolayered tablets of this invention is critical. For instance, if the iron is compressed into the sugar compressioncoated core, and the ascorbic acid compression-layered on one face of this core, stability would still be a problem. The ascorbic acid, although separated from the iron would be exposed to attack by the oxygen and moisture of the atmosphere. It is evident that this arrangement of active ingredients would not be acceptable.
  • a pleasant tasting wetting agent in the spirit of this invention, can be incorporated in the:
  • any physiologically acceptable wetting agent can be used, but we prefer to add Pluronic F-68 powder, a polyoxyethylene-polyoxypropylene condensation product, manufactured by the Wyandotte Chemical Corp, Wyandotte, Michigan, because of its taste.
  • the added wetting agent helps to reduce the incidence of fecal impaction associated with the administration of iron orally.
  • ferrous iron is about 1050 mg. and ascorbic acid is usually dispensed in 2S100 mg. doses, depending upon the individual and the degree of illness.
  • An average dose is about 20 mg. of iron and 50 mg. of ascorbic acid.
  • vitamins and minerals can be incorporated, dependent upon the individual requirements.
  • These medicaments can be added to the granulations by known methods for incorporation into the two-layered tablets of this invention.
  • Various pharmaceutically acceptable dyes may be used in the tablet of this invention to produce two-color and two-tone tablets.
  • Pharmaceutically acceptable flavors may also be added to granulations in the tablet of this invention to mask the taste of iron and ascorbic acid, and render it a more elegant chewable tablet.
  • the two-layered tablet of this invention possesses greater chemical stability of the ascorbic acid; has favorable size characteristics, lending itself to ease of administration; and is pleasant tasting and elegant.
  • FIGURE 1 Exploded outer side-view of the twolayered tablet.
  • One of the layers contains the mannitol coated ascorbic acid core (1).
  • the second layer contains the ferrous fumarate granulation compressed thereon (2).
  • the two granulations are clearly separated from each other by the mannitol coating.
  • the ascorbic acid was blended with mannitol, flavor, sodium cyclamate and acacia.
  • the resulting powder mixture was passed through a 40 mesh screen and then gran ulated with the ethylcellulose-dye-alcohol solution and finally with 213 alcohol.
  • the wet granulation was passed through a 12 mesh screen and dried at 70 to 110 Fahrenheit for 8 hours.
  • the dried granulation was passed through a 16 mesh screen.
  • the lubricants were added and blended thoroughly.
  • the mannitol, methylcellulose, sodium cyclamate and flavor were blended and passed through a 40 mesh screen, then granulated with the dye-water solution and finally with purified water.
  • the wet granulation was passed through a 12 mesh screen and thoroughly dried at 110 Fahrenheit for 12 hours. This dried granulation was passed through a mesh screen.
  • the lubricants were added and blended thoroughly.
  • the ferrous fumarate, mannitol, methylcellulose, sodium cyclamate, and flavor were blended and passed through a mesh screen, then granulated with the dye-water solution and finally with purified water.
  • the wet granulation was passed through a 12 mesh screen and thoroughly dried at 110 Fahrenheit for 12 hours. It was then passed through a 30 mesh screen.
  • the lubricants were added and blended thoroughly.
  • Second Stage Compression of the mannitol coating about the core.
  • EXAMPLE 2 Using the procedure of Example 1, two-layered tablets, wherein one layer consisted of a compression coated core of ascorbic acid, were prepared containing 50 mg. of polyoxyethylene-polyoxypropylene copolymer wetting agent in the ferrous fumarate layer replacing 50 mg. of the mannitol.
  • EXAMPLE 3 Using the procedure of Example 1, two-layered tablets, wherein one layer consisted of a compression coated core of ascorbic acid, were prepared containing 25 mg. ascorbic acid per tablet in place of the 50 mg. of Example 1.
  • EXAMPLE 4 Using the procedure of Example 1, two layered tablets, wherein one layer consisted of a compression coated core of ascorbic acid, were prepared containing sodium ascorbate in amounts equivalent to about mg. ascorbic acid.
  • EXAMPLE 6 Using the procedure of Example 1, two layered tablets, wherein one layer consisted of "a compression coated core of ascorbic acid, were prepared containing ferrous sulfate in an amount equivalent to about 50 mg. of iron.
  • a chewable hematinic vitamin tablet form comprising a pro-compressed vitamin tablet core portion containing ethylcellulose-granulated mannitol and a source of vitamin C, said tablet core portion having smaller dimensions than the desired finished tablet, an inert compression-coated methylcellulosegranulated mannitol barrier coating completely surrounding said vitamin tablet core portion and a hemantinic granulation layer containing methylcellulosegranulated mannitol and a therapeutically acceptable ferrous iron compound, said chewable vitamin tablet form having the hematinic tablet layer compressed to one face of the mannitol-coated precompressed vitamin core portion.

Description

March 17, 1964 1.. N. ELOWE ETAL 3,125,491
CHEWABLE usum'rmc vmum TABLET Filed April 6, 1962 II [III/III,
I I l '0 III III! II a:
INVENTORS. L can; Nam/r E/ouc Gerald James Jae/(s00 Jr:
United States Patent M 3,125,491 CHEWABLE TEMATENTC VlTAMlN TABLET Louis Nash- Elowe and Gerald James Jackson, Jr., Bardonia, N.Y., assignors to American Cyanamid Cor parry, Stamford, (1021111., a corporation of Maine Filed Apr. 6, 1952, Ser. No. 135,664 1 Claim. (Cl. 167-452) This invention relates to novel medicinal chewable tablets. More particularly, this invention relates to a tablet superimposed on a second tablet to form a twolayered tablet, one of these layers consisting of a sugar compression-coated core containing a form of vitamin C, the other layer consisting of a granulation of therapeutic ferrous iron. The chewable tablet of this invention is especially useful for combining incompatible medicaments such as ascorbic acid and iron, in a pleasant tasting single dosage unit.
Therapeutic compositions containing iron for oral and parenteral use are usually administered in concentrated form to people sufiiering from iron deficiency anemia.
The oral administration of therapeutic ferrous iron as the sulfate, fumarate, saccharide, gluconate, lactate, etc., and a form of vitamin C such as ascorbic acid, for use in treating iron deficiency anemias, is well-known. Of the various forms of ferrous iron, ferrous fumarate is well tolerated and generally preferred.
Generally, chewable hematinic tablets are preferred when people are reluctant to take tablets or capsules because of swallowing difiiculties. Children are particularly a problem in this regard. It would also be an advantage to make available to people who take hematinics rather regularly, a pleasant tasting chewable dosage form containing both ascorbic acid and iron in therapeutic amounts.
The actual preparation of an oral dosage form, such as a chewable tablet containing these therapeutic agents, however, prevents certain difficulties, because of the oxidizing effects of iron on ascorbic acid, and the lability of ascorbic acid to oxygen and moisture, especially at higher temperatures. Furthermore, when ascorbic acid decomposes, a gas evolves which could be hazardous in an air-tight package.
In the past, hematinic tablets have been prepared with granulations of ascorbic acid and iron compressed into a single tablet separated by an inert middle layer. However, when these tablets are randomly filled into a package, the iron layer of one tablet is in contact with the ascorbic layer of another tablet, consequently oxidation of the ascorbic acid may occur during storage. This oxidation can be prevented by coating these tablets with sugars, fats, waxes, polyethylene glycol or other known coatings. However, this extra step would add to the manufacturing cost, and in the case of the sugar coating, would add to the unwanted bulk of the tablet.
According to the present invention, a stable, pleasant tasting, two-layered chewable hematinic tablet is prepared as follows: I
(1) Prepare a core containing a therapeutic dose of ascorbic acid.
(2) Compression-coat this core with an inert sugar granulation to form one layer.
(3) Prepare a granulation of a therapeutically acceptable ferrous iron compound.
(4) Compress the iron granulation on one face of the sugar-coated ascorbic acid layer of step 2.
Thus, a two layered tablet is produced containing:
(1) A layer of sugar coated ascorbic acid.
(2) A superimposed layer containing a dose of therapeutically acceptable ferrous iron compound.
The sugar coating on the ascorbic acid must be com- 3,125,491 lc Patented Mar. 17, 1964 pression-coated as is described in Remmington, Practice of Pharmacy, 11th edition, page 406 (1956). Essentially this step involves actually compressing a coating on a core, usually with a tablet press. If the core is pancoated, for instance, the sugar coating is subject to cracking when the iron granulation is compressed superimposed thereon. The sugar must be compression-coated onto the ascorbic acid core in order to produce the two layered tablet of this invention.
Compression should be carried out preferably under low humidity conditions and with thoroughly dried granulations because of the adverse effect of moisture on the ascorbic acid.
The arrangement of the active ingredients in the twolayered tablets of this invention is critical. For instance, if the iron is compressed into the sugar compressioncoated core, and the ascorbic acid compression-layered on one face of this core, stability would still be a problem. The ascorbic acid, although separated from the iron would be exposed to attack by the oxygen and moisture of the atmosphere. It is evident that this arrangement of active ingredients would not be acceptable.
A pleasant tasting wetting agent, in the spirit of this invention, can be incorporated in the:
(1) Core with ascorbic acid, (2) Ferrous fumarate granulation, (3) Sugar granulation around the ascorbic acid.
Any physiologically acceptable wetting agent can be used, but we prefer to add Pluronic F-68 powder, a polyoxyethylene-polyoxypropylene condensation product, manufactured by the Wyandotte Chemical Corp, Wyandotte, Michigan, because of its taste. The added wetting agent, of course, helps to reduce the incidence of fecal impaction associated with the administration of iron orally.
An oral therapeutic dose of ferrous iron is about 1050 mg. and ascorbic acid is usually dispensed in 2S100 mg. doses, depending upon the individual and the degree of illness. An average dose is about 20 mg. of iron and 50 mg. of ascorbic acid.
Other vitamins and minerals can be incorporated, dependent upon the individual requirements. These medicaments can be added to the granulations by known methods for incorporation into the two-layered tablets of this invention.
Various pharmaceutically acceptable dyes may be used in the tablet of this invention to produce two-color and two-tone tablets. Pharmaceutically acceptable flavors may also be added to granulations in the tablet of this invention to mask the taste of iron and ascorbic acid, and render it a more elegant chewable tablet.
The two-layered tablet of this invention possesses greater chemical stability of the ascorbic acid; has favorable size characteristics, lending itself to ease of administration; and is pleasant tasting and elegant.
The tablets of this invention are also illustrated in the attached drawing.
FIGURE 1Exploded outer side-view of the twolayered tablet. One of the layers contains the mannitol coated ascorbic acid core (1). The second layer contains the ferrous fumarate granulation compressed thereon (2).
FIGURE 2Cr0ss-section of the side-view of the tablet showing the ascorbic acid core clearly visible (3); the mannitol coating about the ascorbic acid core (1). The ferrous fumarate granulation (2) compressed thereon. The two granulations are clearly separated from each other by the mannitol coating.
The following'examples are illustrative of the processes and products of this invention and are not to be construed as limiting.
EXAMPLE 1 (A) Preparation of Tablet Cores Each core contains:
Ascorbic acid, U.S.P mg 50.00 Mannitol, NF mg 75.20 Sodium cyclamate, N.F mg 10.00 Acacia, powdered, U.S.P mg 5.00 Ethyicellulose mg 1.20 Dried raspberry flavor mg 2.0
Granulating Solution Ethylcellulose mg 1.2 213 alcohol ml 0.05 Red dye, PD. and C mg 0.10
Lubrication Magnesium stearate, U.S.P mg 2.25 Talc, U.S.P mg 2.25
The ascorbic acid was blended with mannitol, flavor, sodium cyclamate and acacia. The resulting powder mixture was passed through a 40 mesh screen and then gran ulated with the ethylcellulose-dye-alcohol solution and finally with 213 alcohol. The wet granulation was passed through a 12 mesh screen and dried at 70 to 110 Fahrenheit for 8 hours. The dried granulation was passed through a 16 mesh screen. The lubricants were added and blended thoroughly.
(B) Preparation of Sugar Coating Each Mannitol coating contains:
Mannitol, NF "mg" 277.62 Methylcellulose, 400 cps, U.S.P mg 6.00 Sodium cyclamate, NF mg 2.40 Dried lemon flavor mg 3.83
Granulating Solution Purified water rnl 0.055 Yellow dye, PD. and C. mg 0.15
Lubrication Magnesium stearate, U.S.P mg 4.50 Talc, U.S.P mg 4.50
The mannitol, methylcellulose, sodium cyclamate and flavor were blended and passed through a 40 mesh screen, then granulated with the dye-water solution and finally with purified water. The wet granulation was passed through a 12 mesh screen and thoroughly dried at 110 Fahrenheit for 12 hours. This dried granulation was passed through a mesh screen. The lubricants were added and blended thoroughly.
(C) Preparation of Ferrous Fumarate Layer Each ferrous fumarate layer contains:
Ferrous fumarate mg. 60.846 Mannitol, N.F mg 205.704 Methylcellulose, 400 cps mg 6.000 Sodium cyclamate, N.F mg 12.000 Dried spearmint flavor mg 6.25
Granulating Solution Purified water ml 0.06 Green dye, PD. and C. #2 mg 0.2
Lubrication Magnesium stearate, U.S.P mg 4.500 Talc, U.S.P mg 4.500
1 Equivalent to 20 mg. iron.
The ferrous fumarate, mannitol, methylcellulose, sodium cyclamate, and flavor were blended and passed through a mesh screen, then granulated with the dye-water solution and finally with purified water. The wet granulation was passed through a 12 mesh screen and thoroughly dried at 110 Fahrenheit for 12 hours. It was then passed through a 30 mesh screen. The lubricants were added and blended thoroughly.
(D) Compression of Layered Tablet The two layered tablets were compressed as follows:
First Stage: Compression of asorbic acid core.
Second Stage: Compression of the mannitol coating about the core.
Third Stage: Compression of the ferrous fumarate layer to one face of the coated core.
EXAMPLE 2 Using the procedure of Example 1, two-layered tablets, wherein one layer consisted of a compression coated core of ascorbic acid, were prepared containing 50 mg. of polyoxyethylene-polyoxypropylene copolymer wetting agent in the ferrous fumarate layer replacing 50 mg. of the mannitol.
EXAMPLE 3 Using the procedure of Example 1, two-layered tablets, wherein one layer consisted of a compression coated core of ascorbic acid, were prepared containing 25 mg. ascorbic acid per tablet in place of the 50 mg. of Example 1.
EXAMPLE 4 Using the procedure of Example 1, two layered tablets, wherein one layer consisted of a compression coated core of ascorbic acid, were prepared containing sodium ascorbate in amounts equivalent to about mg. ascorbic acid.
I EXAMPLE 5 Using the procedure of Example 1, two layered tablets, wherein one layer consisted of a compression coated core of ascorbic acid, were prepared containing ferrous fumarate in an amount equivalent to about 10 mg. of iron in place of the 60.846 mg. of ferrous fumarate (equivalent to 20 mg. of iron) in Example 1.
EXAMPLE 6 Using the procedure of Example 1, two layered tablets, wherein one layer consisted of "a compression coated core of ascorbic acid, were prepared containing ferrous sulfate in an amount equivalent to about 50 mg. of iron.
Having thus described our invention, we claim:
A chewable hematinic vitamin tablet form comprising a pro-compressed vitamin tablet core portion containing ethylcellulose-granulated mannitol and a source of vitamin C, said tablet core portion having smaller dimensions than the desired finished tablet, an inert compression-coated methylcellulosegranulated mannitol barrier coating completely surrounding said vitamin tablet core portion and a hemantinic granulation layer containing methylcellulosegranulated mannitol and a therapeutically acceptable ferrous iron compound, said chewable vitamin tablet form having the hematinic tablet layer compressed to one face of the mannitol-coated precompressed vitamin core portion.
References Cited in the file of this patent UNITED STATES PATENTS 2,410,110 Taylor Oct. 29, 1946 2,811,483 Alterno et al Oct. 29, 1957 2,822,317 Gulesich et al Feb. 4, 1958 2,887,436 Kloize et al May 19, 1959 2,939,820 Gerber et al. June 7, 1960 2,985,559 Coles May 23, 1961 2,996,431 Barry Aug. 15, 1961 3,019,169 Klumpp et al Jan. 30, 1962 3,048,526 Boswell Aug. 7, 1962 (Qther references on foiiowiug page) FOREIGN PATENTS 807,638 Great Britain Jan. 21, 1959 851,761 Great Britain Oct. 19, 1960 OTHER REFERENCES Atlas-Guide to Using Mannitol, N. F. as a Base in
US3125491D 1962-04-06 Chew able hematinic vitamin tablet Expired - Lifetime US3125491A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18566462A 1962-04-06 1962-04-06

Publications (1)

Publication Number Publication Date
US3125491A true US3125491A (en) 1964-03-17

Family

ID=22681943

Family Applications (1)

Application Number Title Priority Date Filing Date
US3125491D Expired - Lifetime US3125491A (en) 1962-04-06 Chew able hematinic vitamin tablet

Country Status (4)

Country Link
US (1) US3125491A (en)
BE (1) BE629982A (en)
FR (1) FR3472M (en)
GB (1) GB983132A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476571A (en) * 1966-05-19 1969-11-04 Gen Foods Corp Artificially sweetened fruit-flavored product
US4260596A (en) * 1979-08-13 1981-04-07 Bristol-Myers Company Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same
WO1987006128A1 (en) * 1986-04-07 1987-10-22 Clemetson Ab Charles Catechin coated ascorbic acid and method
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US6352713B1 (en) 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
US6440450B1 (en) 1998-07-25 2002-08-27 Sam-Pharmaceutical Co., Ltd. Soft chewable tablet comprising separated active ingredients
US20020187205A1 (en) * 1994-06-20 2002-12-12 K-V Pharmaceutical Company Multi-vitamin and mineral supplements for women
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
WO2004093850A1 (en) 2003-04-24 2004-11-04 Jagotec Ag Tablet with coloured core
US20100196427A1 (en) * 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
DE102011122250A1 (en) * 2011-10-24 2013-04-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Multiphase system, useful e.g. to treat vitamin deficiency, comprises two different phases/layers comprising first phase/layer of active component comprising iron(II) compound, and second phase/layer of active component comprising vitamin
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
US4432975A (en) * 1981-04-13 1984-02-21 Icn Pharmaceuticals, Inc. Process for introducing vitamin B-12 into the bloodstream
CN110327303A (en) * 2019-08-15 2019-10-15 威海百合生物技术股份有限公司 A kind of iron vitamin C tablet and preparation method thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2410110A (en) * 1943-01-14 1946-10-29 Brewer & Company Inc Method of making tablets
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
US2822317A (en) * 1955-12-12 1958-02-04 Smith Kline French Lab Aqueous iron-ascorbic acid preparation
GB807638A (en) * 1956-05-18 1959-01-21 Mallinckrodt Chemical Works Substantially anhydrous ferrous fumarate and a method of preparing same
US2887436A (en) * 1956-05-28 1959-05-19 Pfizer & Co C Pharmaceutical compositions
US2939820A (en) * 1956-06-11 1960-06-07 Pfizer & Co C Aqueous vitamin and mineral compositions
GB851761A (en) * 1958-01-27 1960-10-19 Glaxo Lab Ltd Therapeutic compositions containing ferrous fumarate
US2985559A (en) * 1958-01-27 1961-05-23 Glaxo Lab Ltd Stabilized therapeutic ferrous fumarate aqueous suspensions
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3019169A (en) * 1958-06-23 1962-01-30 Sterling Drug Inc Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2410110A (en) * 1943-01-14 1946-10-29 Brewer & Company Inc Method of making tablets
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
US2822317A (en) * 1955-12-12 1958-02-04 Smith Kline French Lab Aqueous iron-ascorbic acid preparation
GB807638A (en) * 1956-05-18 1959-01-21 Mallinckrodt Chemical Works Substantially anhydrous ferrous fumarate and a method of preparing same
US2887436A (en) * 1956-05-28 1959-05-19 Pfizer & Co C Pharmaceutical compositions
US2939820A (en) * 1956-06-11 1960-06-07 Pfizer & Co C Aqueous vitamin and mineral compositions
GB851761A (en) * 1958-01-27 1960-10-19 Glaxo Lab Ltd Therapeutic compositions containing ferrous fumarate
US2985559A (en) * 1958-01-27 1961-05-23 Glaxo Lab Ltd Stabilized therapeutic ferrous fumarate aqueous suspensions
US3019169A (en) * 1958-06-23 1962-01-30 Sterling Drug Inc Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476571A (en) * 1966-05-19 1969-11-04 Gen Foods Corp Artificially sweetened fruit-flavored product
US4260596A (en) * 1979-08-13 1981-04-07 Bristol-Myers Company Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same
WO1987006128A1 (en) * 1986-04-07 1987-10-22 Clemetson Ab Charles Catechin coated ascorbic acid and method
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
AU597064B2 (en) * 1986-05-27 1990-05-24 Ciba-Geigy Ag Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US20020187205A1 (en) * 1994-06-20 2002-12-12 K-V Pharmaceutical Company Multi-vitamin and mineral supplements for women
US20030068372A1 (en) * 1994-06-20 2003-04-10 Drugtech Corporation Nutritional composition
US6440450B1 (en) 1998-07-25 2002-08-27 Sam-Pharmaceutical Co., Ltd. Soft chewable tablet comprising separated active ingredients
US6444218B2 (en) * 1998-07-25 2002-09-03 Sam-A-Pharmaceuticals Co. Ltd. Soft chewable multivitamin tablet comprising separated active ingredients
US6352713B1 (en) 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
WO2004093850A1 (en) 2003-04-24 2004-11-04 Jagotec Ag Tablet with coloured core
JP2006524230A (en) * 2003-04-24 2006-10-26 ヤゴテック アーゲー Tablet with colored core
US20070148229A1 (en) * 2003-04-24 2007-06-28 Jagotec Ag Tablet with coloured core
JP4908200B2 (en) * 2003-04-24 2012-04-04 ヤゴテック アーゲー Tablet with colored core
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US9504699B2 (en) 2006-08-03 2016-11-29 Hznp Limited Delayed-release glucocorticoid treatment of rheumatoid disease
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US20100196427A1 (en) * 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
DE102011122250A1 (en) * 2011-10-24 2013-04-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Multiphase system, useful e.g. to treat vitamin deficiency, comprises two different phases/layers comprising first phase/layer of active component comprising iron(II) compound, and second phase/layer of active component comprising vitamin

Also Published As

Publication number Publication date
FR3472M (en) 1965-08-09
BE629982A (en)
GB983132A (en) 1965-02-10

Similar Documents

Publication Publication Date Title
US3125491A (en) Chew able hematinic vitamin tablet
US3131123A (en) Enteric tablets and manufacture thereof
KR960005706B1 (en) Oral sustained release acetaminophen formulation and the preparation process thereof
US5711961A (en) Pharmaceutical compositions based on chewing gum and a method for the preparation thereof
US3344029A (en) Sustained release composition
US4851226A (en) Chewable medicament tablet containing means for taste masking
US3048526A (en) Medicinal tablet
EP0312581B1 (en) Pharmaceutical sustained release matrix and process
US7067149B1 (en) Fast disintegrating tablet
US5200193A (en) Pharmaceutical sustained release matrix and process
EP1937287B1 (en) Mixture of iron and copper salts masking metallic taste
DE3723735C2 (en)
CZ2002429A3 (en) Preparation for making a mass with structural integrity
RU96107106A (en) NEW GRANULES FOR REGULATED RELEASE AND PHARMACEUTICAL DRUGS CONTAINING SUCH GRANULES
US20030190355A1 (en) Modified release minerals
RU2456000C2 (en) Mixed iron and copper salts masking metallic taste
EP0833615A1 (en) Nutritional and/or dietary composition and method of using the same
JPH08500834A (en) Naproxen sodium and naproxen combination controlled release tablets
JPS6345216A (en) Long life prescription
US6572891B1 (en) Sublingual oral dosage form
EP0317274B1 (en) Chewable medicament tablet containing means for taste masking
US20090162429A1 (en) Slow-Release Composition, Method for the Preparation Thereof, and Use Thereof
DE3603564C2 (en) Pharmaceutical preparations with analgesic effectiveness based on diclofenac
EP1057472B1 (en) Solid preparation for oral hygiene
WO1992017161A1 (en) Chewable antacid compositions